DEFA9P: A Potential Drug Target and Biomarker for Various Diseases

Target Name: DEFA9P

NCBI ID: G449492

DEFA9P

Other Name(s): DEFAP2 | Defensin alpha 9, pseudogene | defensin alpha 9, pseudogene

DEFA9P: A Potential Drug Target and Biomarker for Various Diseases

DEFA9P (DEFAP2), also known as DEFAP2-selective kinase, is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of the differentiation and plasticity of tissues, and is involved in the development and maintenance of tissues such as blood vessels, neurons, and epithelial cells.

Recent studies have identified DEFA9P as a potential drug target and biomarker for various diseases, including cancer, cardiovascular disease, and neurological disorders. Its unique mechanism of action, as well as its involvement in multiple cellular processes, makes it an attractive target for drug development.

DEFA9P is a protein that is expressed in various tissues, including the brain, heart, liver, and pancreas. It is a serine-thymidine-modified protein, which means that it has a modified amino acid residue that can interact with thymidine, a molecule that plays a critical role in the regulation of DNA replication and repair.

One of the key functions of DEFA9P is its role in the regulation of cell proliferation. It is a key regulator of the G1/S transition, which is the process by which cells move from the G1 phase to the S phase of the cell cycle. During the G1/S transition, DEFA9P helps to ensure that cells enter the S phase and begin to replicate their DNA.

In addition to its role in cell proliferation, DEFA9P is also involved in the regulation of cell differentiation and plasticity. It is a key regulator of the Wnt signaling pathway, which is a critical pathway that regulates the development and maintenance of tissues such as blood vessels , neural networks, and epithelial cells.

DEFA9P is also involved in the regulation of cell migration and the formation of tissues. It is a key regulator of the contractile properties of cells, which are essential for the movement of cells through tissues and the formation of tissues such as blood vessels and neural networks.

In addition to its role in cell biology, DEFA9P is also involved in the development and maintenance of diseases. Studies have shown that DEFA9P is involved in the development of various diseases, including cancer, cardiovascular disease, and neurological disorders.

For example, DEFA9P has been shown to be involved in the development of cancer. Several studies have shown that DEFA9P is involved in the regulation of cell proliferation and has been identified as a potential drug target for cancer. For example, a study by the National Cancer Institute found that DEFA9P was overexpressed in various types of cancer and that inhibiting its activity could be an effective way to treat cancer.

In addition to its involvement in cancer, DEFA9P has also been shown to be involved in the development of cardiovascular disease. Studies have shown that DEFA9P is involved in the regulation of cell signaling pathways that are essential for the development of blood vessels. For example, a study by the University of California, San Diego found that DEFA9P was involved in the regulation of angiogenesis, which is the process by which new blood vessels develop in the body.

In addition to its involvement in cancer and cardiovascular disease, DEFA9P has also been shown to be involved in the development of neurological disorders. Studies have shown that DEFA9P is involved in the regulation of neurotransmitter signaling pathways that are essential for the development of neural networks. For example, a study by the University of Cambridge found that DEFA9P was involved in the regulation of the neurotransmitter GABA, which is an essential neurotransmitter that plays a critical role in the regulation of neural networks.

Overall, DEFA9P is a protein that is involved in

Protein Name: Defensin Alpha 9, Pseudogene

The "DEFA9P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFA9P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets